Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441566 in moderate to severe plaque psoriasis
NCT06073119Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of balinatunfib in plaque psoriasis (6 arms), sponsored by Sanofi. Primary endpoint: 75% or Greater Psoriasis Area and Severity Index Reduction From Baseline at 12 weeks. Started Oct 2023; status: completed.
02
Drugs
balinatunfib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06073119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06073119.